Booster and 3^rd Doses: Who qualifies for what?

Booster for certain populations for Pfizer only:

Following CDC recommendations below, the MCHD is providing booster doses of Pfizer-BioNTech COVID-19 vaccine for certain populations who received their second dose of Pfizer at least 6 months ago:

• people aged 65 years and older should receive a booster shot of Pfizer-BioNTech’s COVID-19 vaccine at least 6 months after their Pfizer-BioNTech primary series, 
• residents aged 18 years and older of long-term care settings should receive a booster shot of Pfizer-BioNTech’s COVID-19 vaccine at least 6 months after their Pfizer-BioNTech primary series, 
• people aged 50–64 years with underlying medical conditions should receive a booster shot of Pfizer-BioNTech’s COVID-19 vaccine at least 6 months after their Pfizer-BioNTech primary series,
• people aged 18–49 years with underlying medical conditions may receive a booster shot of Pfizer-BioNTech’s COVID-19 vaccine at least 6 months after their Pfizer-BioNTech primary series, based on their individual benefits and risks, and.
• people aged 18-64 years who are at increased risk for COVID-19 exposure and transmission because of occupational or institutional setting may receive a booster shot of Pfizer-BioNTech’s COVID-19 vaccine at least 6 months after their Pfizer-BioNTech primary series, based on their individual benefits and risks.

3^rd Dose of Pfizer or Moderna for those immunocompromised

MCHD is now offering a 3rd dose of the Pfizer or Moderna vaccine for those who are moderately to severely immunocompromised. If you meet at least one of the criteria below, you may receive this additional dose provided at least 28 days have passed since your second dose of Pfizer or Moderna. This additional dose is intended to improve immunocompromised people’s response to their initial vaccine series. However, it is not the same as a booster dose, which is given to people when the immune response to a primary vaccine series is likely to have waned over time. MCHD encourages eligible individuals to consult with their medical provider to discuss if an additional dose is appropriate for them. Criteria includes:

• Been receiving active cancer treatment for tumors or cancers of the blood
• Received an organ transplant and are taking medicine to suppress the immune system
• Received a stem cell transplant within the last 2 years or are taking medicine to suppress the immune system
• Moderate or severe primary immunodeficiency (such as DiGeorge syndrome, Wiskott-Aldrich syndrome)
• Advanced or untreated HIV infection
• Active treatment with high-dose corticosteroids or other drugs that may suppress your immune response